HKeyBio Launches the HKEY-AIDMD 3.0--a Next-Generation Platform to Crack the Toughest Challenge in Autoimmune and Allergy Drug Development: Multi-target Combination Strategy Optimization

The newly upgraded HKEY-AIDMD 3.0 model library features nearly 300 autoimmune and allergy-related disease

Asthma and Allergy Drug Development Is Failing Too Often--A Translational Reset Is Needed: HKEY-AIRx™1.0

BOSTON and SUZHOU, China, Jan. 27, 2026 /PRNewswire/ -- HKeyBio, a preclinical CRO focused on autoimmune and

RVAC Medicines announces research collaboration with University of Pennsylvania mRNA Vaccine Pioneer

Inventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery

TYK2/JAK1 Inhibitor AC-201 of Accropeutics Bioscience gained Human Research Ethics Committees (HREC) permission for Phase I

Nona Biosciences and Visterra Partner to Advance Next-Generation Biotherapeutics for Immune-Mediated and Autoimmune Diseases

CAMBRIDGE, Mass., June 12, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing

Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison with Xolair®

PHILADELPHIA, March 2, 2026 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. ("LongBio"), a

Hummingbird Bioscience to Present Preclinical Proof of Concept for Potentially First-In-Class Antibody Targeting Autoimmune Diseases

Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Rα and ST2 for Respiratory and Skin Diseases

HONG KONG, Feb. 14, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the